These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20038447)

  • 1. Influence of fines on the surface energy heterogeneity of lactose for pulmonary drug delivery.
    Ho R; Muresan AS; Hebbink GA; Heng JY
    Int J Pharm; 2010 Mar; 388(1-2):88-94. PubMed ID: 20038447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
    Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):898-909. PubMed ID: 24756910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrainment of lactose inhalation powders: a study using laser diffraction.
    Watling CP; Elliott JA; Cameron RE
    Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of surface heterogeneity of D-mannitol by sessile drop contact angle and finite concentration inverse gas chromatography.
    Ho R; Hinder SJ; Watts JF; Dilworth SE; Williams DR; Heng JY
    Int J Pharm; 2010 Mar; 387(1-2):79-86. PubMed ID: 20006691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
    Dickhoff BH; de Boer AH; Lambregts D; Frijlink HW
    Int J Pharm; 2006 Dec; 327(1-2):17-25. PubMed ID: 16920287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface modification of lactose inhalation blends by moisture.
    Watling CP; Elliott JA; Scruton C; Cameron RE
    Int J Pharm; 2010 May; 391(1-2):29-37. PubMed ID: 20156536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the re-crystallization behaviour of amorphous lactose using the RH-perfusion cell.
    Timmermann IL; Steckel H; Trunk M
    Eur J Pharm Biopharm; 2006 Aug; 64(1):107-14. PubMed ID: 16527465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of carrier surface fines on dry powder inhalation formulations.
    Boshhiha AM; Urbanetz NA
    Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation.
    Traini D; Young PM; Jones M; Edge S; Price R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):243-51. PubMed ID: 16330191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly loaded interactive mixtures for dry powder inhalers: prediction of the adhesion capacity using surface energy and solubility parameters.
    Wagner KG; Dowe U; Zadnik J
    Pharmazie; 2005 May; 60(5):339-44. PubMed ID: 15918581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of ageing, grinding and preheating on the thermal behaviour of alpha-lactose monohydrate.
    Garnier S; Petit S; Mallet F; Petit MN; Lemarchand D; Coste S; Lefebvre J; Coquerel G
    Int J Pharm; 2008 Sep; 361(1-2):131-40. PubMed ID: 18617338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition.
    Kinnunen H; Hebbink G; Peters H; Huck D; Makein L; Price R
    Int J Pharm; 2015 Jan; 478(1):53-59. PubMed ID: 25448567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.